AFM and metabolic dysfunction-associated steatotic liver disease: Further strengths include the extended follow‐up, the wide age range of study participants, the comprehensive adjustments for potential confounders and the use of three fatty liver indices to assess the relevance of afamin in the pathogenesis of MASLD.